Novel Quantitative Liver Steatosis Assessment Method With Ultrasound Harmonic Imaging

Objectives Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%–30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost‐effective, widely accessible, and precis...

Full description

Saved in:
Bibliographic Details
Published inJournal of ultrasound in medicine Vol. 44; no. 1; pp. 77 - 85
Main Authors Gong, Ping, Zhang, Jingke, Huang, Chengwu, Lok, U‐Wai, Tang, Shanshan, Liu, Hui, DeRuiter, Ryan, Petersen, Kendra, Knoll, Kate, Robinson, Kathryn, Watt, Kymberly, Callstrom, Matthew, Chen, Shigao
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.01.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%–30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost‐effective, widely accessible, and precise biomarkers to evaluate liver steatosis. This study aims to assess and compare the diagnostic performance of a novel reference frequency method‐based ultrasound attenuation coefficient estimation (ACE) in both fundamental (RFM‐ACE‐FI) and harmonic (RFM‐ACE‐HI) imaging for detecting and grading liver steatosis. Methods An Institutional Review Board‐approved prospective study was carried out between December 2018 and October 2022. A total number of 130 subjects were enrolled in the study. The correlation between RFM‐ACE‐HI values and magnetic resonance imaging proton density fat fraction (MRI‐PDFF), as well as between RFM‐ACE‐FI values and MRI‐PDFF were calculated. The diagnostic performance of RFM‐ACE‐FI and RFM‐ACE‐HI was evaluated using receiver operating characteristic (ROC) curve analysis, as compared to MRI‐PDFF. The reproducibility of RFM‐ACE‐HI was assessed by interobserver agreement between two sonographers. Results A strong correlation was observed between RFM‐ACE‐HI and MRI‐PDFF, with R = 0.88 (95% confidence interval [CI]: 0.83–0.92; P < .001), while the correlation between RFM‐ACE‐FI and MRI‐PDFF was R = 0.65 (95% CI: 0.50–0.76; P < .001). The area under the ROC (AUROC) curve for RFM‐ACE‐HI in staging liver steatosis grades of S ≥ 1 and S ≥ 2 was 0.97 (95% CI: 0.91–0.99; P < .001) and 0.98 (95% CI: 0.93–1.00; P < .001), respectively, and 0.76 (95% CI: 0.65–0.85) and 0.80 (95% CI: 0.70–0.88) for RFM‐ACE‐FI, respectively. Great reproducibility was achieved for RFM‐ACE‐HI, with an interobserver agreement of R = 0.97 (95% CI: 0.94–0.99; P < .001). Conclusions The novel RFM‐ACE‐HI method offered high liver steatosis diagnostic accuracy and reproducibility, which has important clinical implications for early disease intervention and treatment evaluation.
Bibliography:Ping Gong, Jingke Zhang, U‐Wai Lok and Shigao Chen have potential financial interests (patents/licensing) related to the technology used in this study.
Ping Gong and Jingke Zhang contributed equally to this work.
This study was partially supported by NIH grants R21DK121943 and R01DK127978. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank GE Healthcare for equipment support providing access to RF ultrasound data. Mayo Clinic and some authors have a potential financial interest (patents/licensing) related to the technology used in this study.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0278-4297
1550-9613
1550-9613
DOI:10.1002/jum.16582